Lupin's Ankleshwar Facility Receives EIR from U.S. FDA

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a productspecific Pre-Approval Inspection from March 2 to March 7, 2026.

Nilesh Gupta, Managing Director, Lupin, stated, "We are pleased to receive the EIR from the US FDA for our Ankleshwar facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide."

Shares of Lupin Limited was last trading in BSE at Rs. 2276.75 as compared to the previous close of Rs. 2263.85. The total number of shares traded during the day was 37954 in over 2510 trades.

The stock hit an intraday high of Rs. 2292.10 and intraday low of 2250.00. The net turnover during the day was Rs. 85852170.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals AnkleshwarFacility EIR USFDA